The U.S. Food and Drug Administration has approved the antipsychotic drug Abilify (aripiprazole) for adolescents aged 13 to 17 diagnosed with schizophrenia.
References and Resources
U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for Adolescent Patients with Schizophrenia
Click Here for the news release.
FDA Information Sheet: Aripiprazole (marketed at Abilify)
Click Here to view FDA information.
Abilify Approved for Adolescents with Schizophrenia
November 28, 2007 • Family Medicine, Internal Medicine, Neurology, Pharmacists, Psychiatry & Mental Health, Women’s Health
